EICHOR
● Terminated
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
Condition: Breast Cancer · Sponsor: Ichnos Sciences SA
About this study
The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent ISB1302 in subjects with HER2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (5)
| Ichnos Investigational Site 1 | Gilbert, Arizona, United States | — |
| Ichnos Investigational Site 5 | Los Angeles, California, United States | — |
| Ichnos Investigational Site 4 | Louisville, Kentucky, United States | — |
| Ichnos Investigational Site 2 | Detroit, Michigan, United States | — |
| Ichnos Investigational Site 3 | Philadelphia, Pennsylvania, United States | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03983395